Pharvaris N.V. (PHVS) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 20-F, Pharvaris N.V.'s filing signal continuing negative.

Pharvaris N.V. is a late-stage biopharmaceutical company focused on developing oral therapies for rare diseases, primarily angioedema and other bradykinin-mediated diseases. Its lead product candidate, deucrictibant, is a novel, oral, small-molecule bradykinin B2 receptor antagonist. Deucrictibant is being developed in two formulations: an immediate-release (IR) capsule for on-demand treatment of attacks and an extended-release (XR) tablet for prophylactic treatment. The company has advanced deucrictibant through late-stage clinical trials, including positive Phase 3 data for the IR formulation in hereditary angioedema (HAE) and is preparing to submit a New Drug Application (NDA) to the FDA in the first half of 2026. Pharvaris also has ongoing clinical trials for the XR formulation in HAE and for both formulations in acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH).

The company's primary revenue driver will be the successful commercialization of its deucrictibant product candidates for the treatment and prevention of bradykinin-mediated angioedema. Future revenue will depend on regulatory approvals, market acceptance, and pricing.